Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab safety in urothelial carcinoma with severe renal impairment
ChiCTR2600135148Phase 4Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab in transitional cell carcinoma (TCC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Treatment-related adverse events. Started Jan 2021; status: completed.
02
Drugs
tislelizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2600135148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135148.